Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Day One Biopharmaceuticals Inc

Healthcare US DAWN

NoneUSD
0.00(0%)

Last update at 2026-05-28T21:52:31.938198Z

Day Range

--
LowHigh

52 Week Range

5.6321.50
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap2220.65M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-124.27400M
  • Revenue TTM158.18M
  • Revenue Per Share TTM1.53
  • Gross Profit TTM 140.97M
  • Diluted EPS TTM-1.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -109.29800M -88.35200M -188.91700M -142.18100M -72.75400M
Minority interest - - 0.00000M 0.00000M -2.10900M
Net income -107.32200M -95.49600M -188.91700M -132.17600M -70.44200M
Selling general administrative 120.59M 31.55M 75.54M 61.29M 29.16M
Selling and marketing expenses - 83.90M 0.38M - -
Gross profit 140.97M 125.88M -0.38300M - -
Reconciled depreciation 3.79M 2.03M 0.38M 0.53M 0.20M
Ebit -109.29800M -88.35200M -188.91700M -147.44000M -72.94200M
Ebitda -105.82200M -86.32300M -188.53400M -146.90900M -72.74300M
Depreciation and amortization 3.48M 2.03M 0.38M 0.53M 0.20M
Non operating income net other - - - - -0.01500M
Operating income -127.75000M -217.27000M -206.06400M -146.90900M -72.74300M
Other operating expenses 285.93M 348.43M 206.06M 146.91M 72.74M
Interest expense - - - 4.75M 0.00400M
Tax provision -1.97600M 7.14M 0.00000M - -
Interest income 18.47M 19.70M 17.19M 4.75M 0.00400M
Net interest income - - - 4.75M 0.00400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.97600M 7.14M - -10.00500M -2.31200M
Total revenue 158.18M 131.16M 0.00000M 0.00000M 0.00000M
Total operating expenses 268.72M 343.15M 205.68M 146.91M 72.74M
Cost of revenue 17.21M 5.28M 0.38M - -
Total other income expense net 18.45M 128.92M 17.15M 4.73M -0.01100M
Discontinued operations - - - - -
Net income from continuing ops -107.32200M -95.49600M -188.91700M -142.18100M -72.75400M
Net income applicable to common shares -107.32200M -95.49600M -188.91700M -142.18100M -170.63900M
Preferred stock and other adjustments - - - - 99.99M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 507.83M 582.79M 376.05M 349.06M 289.82M
Intangible assets 18.02M 15.63M - - -
Earning assets - - - - -
Other current assets 10.93M 13.41M 2.35M 1.01M 1.01M
Total liab 66.67M 80.04M 29.51M 17.02M 8.67M
Total stockholder equity 441.16M 502.75M 346.54M -269.66800M -127.48700M
Deferred long term liab - - - - -
Other current liab 54.62M 68.62M 1.04M 15.95M 0.10M
Common stock 0.01000M 0.01000M 0.00900M 0.00700M 0.00600M
Capital stock 0.01000M 0.01000M 0.00900M 0.00700M 0.00600M
Retained earnings -661.40300M -554.08100M -458.58500M -269.66800M -127.48700M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.47M 0.17M
Cash 197.08M 124.97M 230.78M 85.26M 284.31M
Cash and equivalents - - - - -
Total current liabilities 60.52M 73.45M 29.51M 16.61M 8.66M
Current deferred revenue 2.00M 1.55M 25.48M - 6.61M
Net debt -194.28500M -122.36600M -230.37600M -84.44900M -284.08900M
Short term debt 0.17M 0.01000M 0.41M 0.41M 0.20M
Short long term debt - - - - -
Short long term debt total 2.79M 2.60M 0.41M 0.81M 0.22M
Other stockholder equity 1102.49M 1056.74M 805.11M 0.06M -0.00600M
Property plant equipment 4.48M 4.71M - 0.02M 0.06M
Total current assets 485.10M 562.33M 375.27M 347.87M 289.37M
Long term investments - - - - -
Net tangible assets - - - 332.04M 281.15M
Short term investments 244.03M 406.75M 135.56M 257.01M -
Net receivables 26.73M 13.88M - - -
Long term debt - - - - -
Inventory 6.33M 3.32M - - -
Accounts payable 3.73M 3.26M 2.58M 0.26M 1.74M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.07M 0.08M 0.00900M -0.07100M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00700M 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -269.66800M -127.48700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.23M 0.12M 0.21M 0.47M 0.17M
Deferred long term asset charges - - - - -
Non current assets total 22.73M 20.46M 0.77M 1.19M 0.45M
Capital lease obligations 2.79M 2.60M 0.41M 0.81M 0.22M
Long term debt total 0.00000M 0.00000M - 0.00000M 0.00000M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 178.44M -230.99400M 128.38M -255.04800M -8.00000M
Change to liabilities - - - 7.76M 6.66M
Total cashflows from investing activities 174.65M -230.99400M 128.38M -255.07400M -8.00000M
Net borrowings - - - - -
Total cash from financing activities 1.22M 203.29M 164.00M 165.90M 297.12M
Change to operating activities - - - 8.05M 1.15M
Net income -107.32200M -95.49600M -188.91700M -142.18100M -72.75400M
Change in cash 72.11M -105.81600M 145.52M -199.04700M 240.58M
Begin period cash flow 124.97M 230.78M 85.26M 284.31M 43.73M
End period cash flow 197.08M 124.97M 230.78M 85.26M 284.31M
Total cash from operating activities -103.75700M -78.11300M -146.85300M -109.87400M -48.53900M
Issuance of capital stock 0.00000M 178.18M 161.41M 161.61M 296.80M
Depreciation 3.48M 2.03M 0.38M 0.53M 0.20M
Other cashflows from investing activities -3.46800M 35.90M -3.00000M -255.04800M -8.00000M
Dividends paid - - - - -
Change to inventory -2.86000M -3.24300M 0.00000M - -
Change to account receivables -12.85900M -13.87600M 0.00000M - -
Sale purchase of stock 1.09M 25.11M 1.25M 0.64M 0.32M
Other cashflows from financing activities 1.22M 25.11M 2.59M 3.65M 129.76M
Change to netincome - - - 27.24M 13.32M
Capital expenditures 0.32M 2.17M 3.22M 0.03M 8.00M
Change receivables - - - - -
Cash flows other operating - - - -2.75500M 11.78M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -199.04700M 240.58M
Change in working capital -28.94200M 26.48M 9.42M 6.56M 2.69M
Stock based compensation 44.39M 48.26M 39.34M 27.24M 13.32M
Other non cash items -15.35700M -59.38900M -7.07800M -2.03000M 8.00M
Free cash flow -104.07700M -80.28200M -150.07700M -109.90000M -56.53900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DAWN
Day One Biopharmaceuticals Inc		 - -% - - - 14.04 5.03 11.27 -7.1769
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Day One Biopharmaceuticals Inc

1800 Sierra Point Parkway, Brisbane, CA, United States, 94005

Key Executives

Name Title Year Born
Dr. Jeremy Bender M.B.A., Ph.D. CEO, Pres & Director 1972
Dr. Samuel C. Blackman M.D., Ph.D. Co-Founder & Chief Medical Officer 1969
Ms. Julie Papanek Grant M.B.A. Co-Founder & Director 1982
Mr. Charles N. York II COO, CFO & Sec. 1977
Dr. Mike Preigh Ph.D. Chief of Technology Operations NA
Mr. Adam Dubow Gen. Counsel 1967
Ms. Jaa Roberson Chief People Officer NA
Dr. Davy Chiodin Ph.D., Pharm.D. Chief Devel. Officer NA
Dr. Jeremy Bender M.B.A., Ph.D. CEO, President & Director 1971
Dr. Samuel C. Blackman M.D., Ph.D. Co-Founder and Head of R&D 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.